Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate

Ann Hematol. 2019 Mar;98(3):801-803. doi: 10.1007/s00277-019-03611-3. Epub 2019 Jan 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carboplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Dendritic Cells* / metabolism
  • Dendritic Cells* / pathology
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Fatal Outcome
  • Hematologic Neoplasms* / diagnosis
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / metabolism
  • Hematologic Neoplasms* / pathology
  • Humans
  • Ifosfamide / administration & dosage
  • Male
  • Prednisone / administration & dosage
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / metabolism
  • Skin Neoplasms* / pathology
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Ifosfamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • ICE protocol 2